Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Breast Neoplasms 8Lymphoma, Large B-Cell, Diffuse 3Leukemia, Lymphocytic, Chronic, B-Cell 3Carcinoma, Hepatocellular 3Waldenstrom Macroglobulinemia 2Stomach Neoplasms 2Sezary Syndrome 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Mycosis Fungoides 2Melanoma 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Leukemia, Large Granular Lymphocytic 2Leukemia, Hairy Cell 2Intraocular Lymphoma 2Gallbladder Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Triple Negative Breast Neoplasms 1Thymoma 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Recurrent Squamous Cell Carcinoma of the Nasopharynx 1

Interventions

Doxorubicin 9Specimen Handling 7Sorafenib 7Erlotinib Hydrochloride 7Oxaliplatin 6Magnetic Resonance Spectroscopy 6Leucovorin 6Fluorouracil 5Thalidomide 4Radiofrequency Ablation 4Bevacizumab 4tremelimumab 3cediranib 3cabozantinib 3Trastuzumab 3Pharmacogenomic Testing 3Nivolumab 3Neoadjuvant Therapy 3Melphalan 3MK 2206 3Irinotecan 3Fluorodeoxyglucose F18 3Dasatinib 3Cisplatin 3Chemotherapy, Adjuvant 3Bortezomib 3Biopsy 3AZD 6244 3trametinib 2sargramostim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Carcinoma, Hepatocellular × MK 2206 × Clear all
NCT01425879 2016-06-17

MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
8 enrolled 8 charts
Gastrointestinal

Gallbladder Neoplasms, Carcinoma, Hepatocellular

NCT01239355 2015-10-05

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

National Cancer Institute (NCI)

Phase 2 Terminated
15 enrolled 6 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT01859182 2014-09-09

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡